Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Mediafeed on MSN
The P-Shot: How long does it last & what’s the cost?
This article was reviewed by Kelly Brown MD, MBA. Would you inject your own blood into your privates if it meant better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback